Pandemic Grief and Loss: Complicated Bereavement, Disenfranchised Grief, and Collective Trauma — Clinical Mechanisms, Diagnosis, and Treatment

The COVID-19 pandemic produced a bereavement crisis of unprecedented scale in the modern era. As of mid-2023, the World Health Organization estimated over 6.9 million confirmed COVID-19 deaths globally, with excess mortality analyses suggesting the true toll exceeds 15 million. Each death left an estimated 5 to 9 close bereaved individuals, yielding conservative estimates that between 35 and 130 million people worldwide experienced acute grief directly attributable to COVID-19 mortality alone. This figure does not account for the vast landscape of non-death losses — loss of employment, social connection, identity, health, safety, and developmental milestones — that defined the pandemic experience for billions.

What made pandemic grief clinically distinctive was not merely its scale but its context. The conditions surrounding death and mourning during COVID-19 systematically disrupted nearly every factor known to facilitate adaptive grief processing: the ability to be present at the bedside, to engage in culturally meaningful funeral rituals, to receive in-person social support, and to make sense of the death within a coherent narrative framework. Emerging epidemiological data indicate that these contextual factors substantially elevated the risk for prolonged grief disorder (PGD), a diagnostic entity newly codified in both the DSM-5-TR and ICD-11 during the pandemic itself. Understanding how the pandemic altered grief trajectories — through neurobiological, psychological, and sociocultural mechanisms — is essential for clinicians navigating the long aftermath of collective loss.

This article provides a deep clinical review of pandemic-related bereavement, covering the neurobiology of grief and its complications, diagnostic frameworks and pitfalls, epidemiological data, treatment modalities and their comparative effectiveness, and the specific phenomena of disenfranchised grief and collective trauma that characterized the COVID-19 era.

Normal, or integrated, grief activates a complex interplay of neural systems governing attachment, reward, emotional regulation, and cognitive appraisal. Understanding these systems clarifies why some individuals transition from acute grief to prolonged grief disorder (PGD) and how pandemic conditions may have potentiated that transition.

Attachment and Reward Circuitry

The neuroscience of grief is fundamentally the neuroscience of disrupted attachment bonds. Mary-Frances O'Connor's landmark neuroimaging research demonstrated that bereaved individuals viewing photographs of the deceased show robust activation of the nucleus accumbens, a key node in the mesolimbic dopamine reward circuit. This finding, published in NeuroImage (2008), was particularly pronounced in individuals with complicated grief, suggesting that the deceased continues to function as a reward stimulus — the brain has not updated its predictive model of the attachment figure's availability. The dopaminergic system, particularly D2 receptor signaling in the ventral striatum, thus appears to encode a form of persistent yearning or craving analogous to mechanisms observed in addiction neuroscience.

In adaptive grief, the prefrontal cortex — specifically the dorsolateral prefrontal cortex (dlPFC) and the ventromedial prefrontal cortex (vmPFC) — gradually modulates this reward-driven yearning, facilitating what George Bonanno has described as a flexible oscillation between loss-oriented and restoration-oriented processing. In PGD, this top-down regulation appears impaired. Functional connectivity studies reveal reduced coupling between the vmPFC and the amygdala in complicated grief, paralleling findings in PTSD and suggesting shared deficits in extinction learning and emotional regulation.

The Default Mode Network and Rumination

Grief engages the default mode network (DMN) — including the posterior cingulate cortex, medial prefrontal cortex, and angular gyrus — regions associated with self-referential processing, autobiographical memory, and mental simulation of others' perspectives. In PGD, DMN hyperactivation during grief-related cues has been observed, correlating with ruminative yearning and intrusive mental representations of the deceased. Pandemic-specific factors such as prolonged isolation and reduced access to restorative activities may have sustained DMN-dominant processing states, limiting engagement of task-positive networks associated with adaptive coping.

Stress Systems: HPA Axis and Inflammatory Cascades

Bereavement activates the hypothalamic-pituitary-adrenal (HPA) axis, elevating cortisol levels during the acute grief period. Chronic grief is associated with a dysregulated cortisol profile — blunted diurnal slope and elevated evening cortisol — a pattern that overlaps with profiles seen in major depression and chronic PTSD. The inflammatory sequelae are clinically significant: bereaved individuals, particularly those with complicated grief, show elevated levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). A seminal study by Fagundes et al. (2019) demonstrated that widowed older adults with high grief severity had significantly elevated pro-inflammatory cytokines up to two years post-loss, contributing to the well-documented increase in cardiovascular morbidity and mortality during bereavement — the so-called "widowhood effect," with meta-analytic data indicating a 41% increased mortality risk in the first six months after spousal bereavement.

Genetic and Epigenetic Vulnerability

Not all bereaved individuals develop PGD, and genetic factors partially account for differential vulnerability. The serotonin transporter gene (5-HTTLPR) short allele, well-studied as a moderator of stress-related psychopathology, has been implicated in greater grief severity following loss. Polymorphisms in the oxytocin receptor gene (OXTR) — particularly variants associated with reduced oxytocin receptor availability — appear to moderate the relationship between attachment insecurity and grief complications, consistent with oxytocin's role in social bonding and separation distress. Epigenetic modifications, including altered methylation patterns at the FKBP5 locus (a glucocorticoid receptor co-chaperone), have been reported in bereaved individuals with persistent grief, suggesting that bereavement can produce lasting changes in stress-response gene regulation.

Pandemic-Specific Neurobiological Amplifiers

COVID-19 created a neurobiological "perfect storm" for complicated grief. Chronic social isolation reduced oxytocin and endogenous opioid signaling that normally buffers separation distress. Persistent threat appraisal maintained elevated sympathetic nervous system tone and amygdala reactivity, blurring the neurobiological boundary between grief and trauma. The absence of physical contact at the bedside — touch being a potent activator of the C-tactile afferent system mediating social buffering — removed a critical modulator of stress physiology during the acute bereavement period.

Understanding the epidemiology of pandemic-era grief requires distinguishing between normal grief responses, which are universal among the bereaved, and clinically significant prolonged grief disorder, which develops in a subset of individuals.

Pre-Pandemic Baseline Rates

Prior to the pandemic, meta-analytic evidence (Lundorff et al., 2017) estimated that approximately 9.8% of bereaved adults develop prolonged or complicated grief, with estimates ranging from 6% to 15% depending on the population studied, the loss circumstances, and the diagnostic criteria applied. Rates were consistently higher following violent death (approximately 16–25%), sudden or unexpected loss, and loss of a child (approximately 12–20%).

Pandemic-Era Prevalence

Multiple large-scale studies have documented substantially elevated PGD rates during the COVID-19 pandemic:

• A systematic review and meta-analysis by Tang and Xiang (2021) examining 12 studies across multiple countries found a pooled PGD prevalence of approximately 22% among individuals bereaved during COVID-19 — more than double the pre-pandemic baseline.
• A large UK study by Eisma et al. (2021) found that individuals bereaved during the pandemic reported significantly higher grief symptoms than those bereaved before it, after controlling for time since loss and relationship to the deceased.
• A cross-sectional study from Italy (Bertuccio & Runion, 2020) reported that over 50% of pandemic-bereaved participants scored above clinical cutoffs for complicated grief on the Inventory of Complicated Grief (ICG), though this likely reflects acute grief elevation rather than the persistence required for PGD diagnosis.
• In the United States, NIMH-funded research estimated that by early 2022, approximately 9 million Americans had lost a close family member to COVID-19, with an estimated 1–2 million at high risk for PGD based on known conversion rates and elevated pandemic risk factors.

Disproportionate Impact

Epidemiological data consistently reveal that pandemic grief burden was not equally distributed. Black, Latino, and Indigenous communities in the United States experienced age-adjusted COVID-19 death rates 1.5 to 2.5 times higher than white populations, concentrating bereavement disproportionately. Socioeconomic marginalization compounded the grief burden through reduced access to mental health care, higher rates of job loss, and greater exposure to multiple concurrent losses. Data from the COVID Collaborative indicated that approximately 1 in 4 Black Americans lost someone close to COVID-19 compared to roughly 1 in 7 white Americans. The intersection of grief with structural racism, health disparities, and historical trauma amplified the risk for both PGD and associated comorbidities in these communities.

The inclusion of Prolonged Grief Disorder (PGD) in both the DSM-5-TR (2022) and ICD-11 (2019/2022) represented a watershed moment in bereavement research, providing a standardized diagnostic framework during a period of historic need. However, the two systems differ in important ways, and clinicians must navigate several differential diagnosis challenges.

DSM-5-TR Criteria for Prolonged Grief Disorder

The DSM-5-TR classifies PGD under Trauma- and Stressor-Related Disorders. Core criteria include:

• Criterion A: Death of a close person at least 12 months prior (6 months for children and adolescents).
• Criterion B: Since the death, a persistent and pervasive grief response characterized by intense yearning/longing for the deceased or preoccupation with thoughts or memories of the deceased (in children, preoccupation may focus on the circumstances of the death).
• Criterion C: At least 3 of 8 additional symptoms experienced to a clinically significant degree and nearly every day for at least the last month: (1) identity disruption, (2) marked sense of disbelief, (3) avoidance of reminders, (4) intense emotional pain, (5) difficulty with reintegration (e.g., engaging with friends, pursuing interests, planning for the future), (6) emotional numbness, (7) feeling that life is meaningless, (8) intense loneliness.
• Criterion D: Clinically significant distress or functional impairment.
• Criterion E: Duration and severity exceed expected social, cultural, or religious norms.

ICD-11 Prolonged Grief Disorder

The ICD-11 definition requires only a 6-month duration rather than the DSM-5-TR's 12 months, potentially capturing cases earlier. Its symptom requirements are somewhat more parsimonious, centering on persistent and pervasive longing or preoccupation accompanied by intense emotional pain (e.g., sadness, guilt, anger, denial, difficulty accepting the death, feeling one has lost a part of oneself, inability to experience positive mood). The ICD-11 explicitly notes cultural contextualization as essential.

Clinical Implications of Divergent Duration Criteria

The 12-month vs. 6-month duration threshold is not merely academic. During the pandemic, many clinicians encountered patients at 6–11 months post-loss with severe, functionally impairing grief that met ICD-11 but not DSM-5-TR criteria. Research from the Yale Bereavement Study and others suggests that the trajectory of PGD is largely established by 6 months, with relatively few spontaneous remissions occurring between months 6 and 12. The DSM-5-TR's longer threshold was intended to reduce false positives, but may delay treatment access in some cases.

Differential Diagnosis Pitfalls

Several conditions share phenomenological overlap with PGD, and accurate differentiation is essential:

• PGD vs. Major Depressive Disorder (MDD): The most common diagnostic confusion. While sadness, withdrawal, and functional impairment occur in both, PGD is distinguished by the centrality of yearning for the specific deceased person, identity disruption related to the death, and preoccupation with the deceased or circumstances of death. MDD features more generalized anhedonia, worthlessness, and psychomotor disturbance not specifically tied to the loss. Comorbidity is common: approximately 30–50% of PGD cases meet concurrent MDD criteria, but PGD remains a distinct predictor of impairment after controlling for depression severity.
• PGD vs. PTSD: When death occurs under traumatic circumstances — as many COVID-19 deaths did, particularly those involving ICU deaths, ventilator imagery, or the inability to be present — PTSD symptomatology may dominate. Intrusive re-experiencing in PTSD centers on the traumatic event, while PGD intrusions center on the lost person and relationship. Avoidance in PTSD targets trauma reminders; in PGD, it targets reminders of the loss itself. Comorbidity is again substantial: approximately 25–40% of traumatically bereaved individuals meet criteria for both conditions.
• PGD vs. Adjustment Disorder: Adjustment disorders related to bereavement may present with clinically significant distress but lack the specific constellation of yearning, identity disruption, and the persistent preoccupation characteristic of PGD.
• Normal Grief: This is perhaps the most consequential differential. Cultural variation in grief expression is enormous, and clinicians must resist pathologizing intense grief that is normative within a given cultural context. The DSM-5-TR and ICD-11 both emphasize that cultural expectations must be considered, but provide limited operational guidance. During the pandemic, clinicians also had to contend with the fact that grief in the context of ongoing collective trauma may appear "prolonged" because the traumatic context itself is prolonged, not because intrinsic grief processing has stalled.

The concept of disenfranchised grief, developed by Kenneth Doka in 1989, refers to grief that is not openly acknowledged, socially validated, or publicly mourned. Doka identified several mechanisms of disenfranchisement: the relationship is not recognized (e.g., ex-partners, friends, colleagues), the loss is not acknowledged as significant (e.g., non-death losses, perinatal loss), the griever is not recognized as capable of grieving (e.g., children, individuals with intellectual disability), or the circumstances of death are stigmatized.

The COVID-19 pandemic vastly expanded the population experiencing disenfranchised grief across multiple dimensions:

Disenfranchised Non-Death Losses

Billions of people worldwide experienced significant losses that were rarely framed as losses meriting grief: canceled weddings, missed graduations, disrupted developmental transitions, loss of businesses, loss of health (long COVID), loss of reproductive opportunities, and loss of the assumptive world of safety and predictability. These losses, while not involving death, activate many of the same attachment, identity, and meaning-making processes as bereavement. Research by Albuquerque et al. (2021) found that non-death pandemic losses were associated with grief symptoms comparable in severity to mild-to-moderate bereavement responses, yet individuals experiencing them often reported feeling that their distress was "not valid" or "selfish" given the death toll.

Healthcare Worker Grief

Healthcare workers experienced repeated patient deaths under conditions that prevented normal emotional processing: the volume of deaths exceeded the capacity for individualized mourning, institutional cultures often did not recognize patient deaths as personal losses, and the relentless pace of care left no temporal space for grief. Studies from multiple countries documented that 40–60% of ICU nurses and physicians during COVID-19 surges reported significant grief symptoms, frequently co-occurring with moral injury — the distress resulting from actions (or inaction) that violated one's moral code, such as enacting triage protocols that allocated ventilators away from certain patients. This grief was profoundly disenfranchised: the professional role that exposed workers to loss simultaneously required them to suppress its emotional impact.

Grief in Marginalized Communities

Disenfranchisement compounded structural inequities. Undocumented immigrants who lost family members often could not access formal support services or apply for bereavement-related financial assistance. Incarcerated individuals — who experienced significant loss during the pandemic given the devastating spread of COVID-19 in correctional facilities — had virtually no access to grief support, funeral attendance, or communal mourning. LGBTQ+ individuals who lost partners in contexts where their relationships were not recognized by families of origin faced disenfranchisement of both the relationship and the loss.

Politicization of Death

A feature unique to the COVID-19 pandemic was the politicization of the cause of death itself. When public discourse questioned whether COVID-19 deaths were "real," whether death counts were inflated, or whether the deceased bore responsibility for their own death through vaccination refusal, bereaved individuals faced a form of disenfranchisement that directly attacked the reality and legitimacy of their loss. This constituted what Doka later termed "disenfranchisement of the cause of death" and created a particularly toxic grief environment in which the griever's pain was not merely unsupported but actively disputed.

The pandemic instantiated a form of collective trauma — a shared experience of adversity that disrupts the social fabric, challenges collective meaning systems, and undermines the group's sense of safety and continuity. This concept, developed by Kai Erikson following the 1972 Buffalo Creek flood and elaborated by numerous scholars since, applies to events that overwhelm not just individual coping resources but communal ones.

Characteristics of Pandemic Collective Trauma

COVID-19 exhibited several features that distinguish it from other collective traumas:

• Prolonged temporal course: Unlike discrete events such as earthquakes or terrorist attacks, the pandemic unfolded over years, preventing the temporal demarcation ("before" and "after") that facilitates collective meaning-making and recovery.
• Invisible and ubiquitous threat: The pathogen was invisible, present everywhere, and transmitted through the fundamental human act of proximity, making normal social behavior itself a source of danger.
• Disruption of collective mourning: Funeral restrictions, social distancing mandates, and travel bans prevented the communal rituals that have served, across virtually all human cultures, as the primary mechanism for processing collective grief.
• Erosion of shared reality: Political polarization around pandemic response measures fragmented the shared narrative that typically emerges after collective trauma, preventing the communal sense-making that Janoff-Bulman identifies as critical for assumptive world reconstruction.

Psychological Impact at the Population Level

Large-scale epidemiological studies documented significant elevations in psychopathology during the pandemic. A meta-analysis by Santomauro et al. (2021), published in The Lancet, estimated an additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders attributable to the COVID-19 pandemic globally in 2020 alone, representing a 27.6% and 25.6% increase over pre-pandemic baseline rates, respectively. These figures capture the broader mental health impact of collective trauma but do not specifically index grief.

Ambiguous Loss

Pauline Boss's concept of ambiguous loss proved highly relevant during the pandemic. Boss distinguishes two types: physical absence with psychological presence (the person is gone but not confirmed dead) and physical presence with psychological absence (the person is present but cognitively or emotionally gone). The pandemic produced widespread experiences of both forms. Families unable to see loved ones who died in sealed hospital rooms sometimes experienced a form of the first type: the absence of visual confirmation of death impeded grief processing. The second type manifested when long COVID, pandemic-related substance use, or severe depression rendered a family member physically present but fundamentally changed.

Post-Traumatic Growth at the Collective Level

It is clinically important to note that collective trauma does not uniformly produce pathology. Research on post-traumatic growth (Tedeschi & Calhoun, 2004) and resilience (Bonanno, 2004) consistently demonstrates that the majority of individuals exposed to adversity — typically 50–65% — exhibit a resilient trajectory characterized by transient distress followed by return to baseline functioning. Pandemic-specific studies have documented post-traumatic growth in areas including strengthened close relationships, revised life priorities, and enhanced sense of personal strength, though these findings do not negate the severity of impact on the substantial minority who develop chronic difficulties.

The treatment literature for PGD has matured significantly over the past two decades, with several approaches demonstrating efficacy in randomized controlled trials. The pandemic accelerated both the need for these treatments and their adaptation to telehealth delivery.

Prolonged Grief Disorder Therapy (PGDT) / Complicated Grief Treatment (CGT)

Developed by M. Katherine Shear and colleagues at Columbia University, Complicated Grief Treatment (CGT) — now termed Prolonged Grief Disorder Therapy (PGDT) — is the most extensively studied psychotherapy for PGD. CGT integrates elements of interpersonal therapy (IPT), cognitive-behavioral therapy (CBT), and motivational interviewing, structured around dual-process model principles: alternating focus on loss-oriented processing (revisiting the story of the death, imaginal conversations with the deceased) and restoration-oriented activities (setting personal goals, rebuilding social connections).

The landmark Shear et al. (2005) RCT, published in JAMA, compared CGT to interpersonal therapy (IPT) in 95 adults with complicated grief. CGT produced a response rate of 51% versus 28% for IPT (response defined as ≥20-point improvement on the ICG and a clinician rating of much or very much improved). Time to response was also significantly faster with CGT. A subsequent larger trial, Shear et al. (2014), compared CGT alone, CGT plus citalopram, citalopram alone, and placebo in 395 participants. CGT (with or without citalopram) produced response rates of approximately 70%, compared to roughly 32% for citalopram alone — a striking differential that established psychotherapy as the primary treatment modality. Citalopram added modest benefit when combined with CGT, primarily for co-occurring depressive symptoms, but was not effective as monotherapy for grief. The NNT for CGT versus IPT in the 2005 trial was approximately 4 to 5.

Cognitive-Behavioral Therapy for Grief

Paul Boelen and colleagues developed a CBT-based protocol for PGD that targets maladaptive grief cognitions (e.g., catastrophic misinterpretations of grief reactions, self-blame) and behavioral avoidance patterns. A key RCT by Boelen et al. (2007) compared exposure-focused CBT, cognitive restructuring, and supportive counseling. The combined CBT protocol (exposure + cognitive restructuring) produced the largest effect sizes (Cohen's d = 0.87 on grief symptom measures), with exposure components appearing to be the primary active ingredient. Response rates in CBT trials typically range from 45–65%, broadly comparable to CGT though direct head-to-head comparisons are limited.

Internet-Based Interventions

Wagner et al. developed an internet-based CBT intervention for complicated grief that demonstrated efficacy in multiple RCTs. A trial by Kersting et al. (2013) found large effect sizes (d = 1.09 for grief, d = 0.89 for depression) for a structured 5-week internet writing intervention compared to waitlist control. These findings gained enormous practical importance during the pandemic when in-person therapy was inaccessible for many bereaved individuals. Subsequent pandemic-era adaptations of both CGT and CBT protocols to videoconference delivery showed preliminary effectiveness, though RCT data specific to pandemic-bereaved telehealth samples are still emerging.

Pharmacotherapy

No medication has FDA approval specifically for PGD. The evidence base is limited:

• SSRIs: As noted, the Shear et al. (2014) trial found citalopram ineffective as monotherapy for grief symptoms (though it modestly improved comorbid depression). Escitalopram and sertraline have shown limited benefit in open-label studies. SSRIs may address comorbid MDD or anxiety but should not be relied upon as primary treatment for PGD.
• Naltrexone: Based on the hypothesis that prolonged grief involves dysregulated opioid-mediated attachment systems, a small pilot study explored naltrexone for PGD. Results were inconclusive and this remains experimental.
• Psychedelic-Assisted Therapy: Psilocybin-assisted therapy is under investigation for existential distress related to terminal illness (Griffiths et al., 2016) and is being explored for grief. Phase 2 trials are in early stages; no efficacy data specific to PGD are yet available.

Comparative Effectiveness Summary

The clearest available evidence supports CGT/PGDT as the first-line treatment for PGD, with CBT-based grief protocols as a well-supported alternative. Head-to-head comparisons between CGT and CBT for grief are lacking, but effect sizes are broadly similar across trials (d = 0.7–1.1 for grief symptom reduction). Pharmacotherapy alone is insufficient for PGD. Combined CGT plus SSRI is reasonable when significant comorbid depression is present, with the SSRI targeting depressive symptoms rather than grief per se.

Prolonged grief disorder rarely occurs in isolation. Understanding comorbidity patterns is essential for treatment planning and prognostication.

PGD and Major Depressive Disorder

Comorbid MDD is present in approximately 30–50% of PGD cases across studies. The two conditions share some phenomenological overlap (sadness, withdrawal, sleep disruption) but are factorially distinguishable: yearning and identity disruption load on a PGD factor, while anhedonia, psychomotor retardation, and generalized worthlessness load on an MDD factor. Critically, PGD predicts functional impairment and suicidal ideation independently of MDD severity, underscoring the clinical importance of assessing for PGD even when depression is the presenting complaint. Suicidal ideation rates in PGD range from 30–45%, and are further elevated when comorbid MDD is present.

PGD and PTSD

Co-occurring PTSD is particularly common when death occurred under traumatic circumstances — as many pandemic deaths did. Estimates of PGD-PTSD comorbidity in traumatically bereaved populations range from 25–40%. Treatment sequencing matters clinically: when both are present, addressing traumatic imagery (through prolonged exposure or EMDR) before or concurrent with grief-focused work may be necessary, as unresolved trauma can impede grief processing. CGT incorporates trauma exposure elements, which may explain part of its efficacy in traumatically bereaved samples.

PGD and Substance Use Disorders

Bereaved individuals are at elevated risk for problematic substance use. During the pandemic, this risk was compounded by social isolation, economic distress, and widespread increases in alcohol and drug consumption at the population level. A study by Galea et al. (2020) noted that U.S. alcohol sales increased by 54% during the initial lockdown period. Substance use complicates PGD treatment by impairing emotional processing, disrupting sleep, and introducing secondary losses (e.g., job loss, relationship damage). Integrated treatment addressing both grief and substance use simultaneously is recommended, though specific RCTs targeting this comorbidity are limited.

PGD and Physical Health

The "bereavement effect" on physical health is robust. Beyond the cardiovascular mortality increase described earlier, PGD is associated with immune dysregulation (reduced natural killer cell activity, impaired vaccine response), increased healthcare utilization, and elevated risk for new-onset medical conditions. During the pandemic, the compounding of grief-related immune suppression with COVID-19 infection risk created a particularly dangerous synergy for bereaved older adults.

Identifying modifiable and non-modifiable risk factors for poor grief outcomes is essential for clinical triage and early intervention.

Risk Factors for PGD

A large body of prospective research, synthesized in the meta-analysis by Lobb et al. (2010), identifies the following as consistent predictors of PGD:

• Relationship to the deceased: Loss of a child carries the highest risk (PGD rates of 12–20%), followed by spousal loss. Pandemic data suggest that loss of a parent by young or middle-aged adults was particularly impactful due to the unexpectedness of many COVID-19 deaths in previously healthy individuals.
• Attachment style: Anxious attachment is the strongest and most consistent psychological predictor of PGD across studies (correlation with grief severity: r = 0.30–0.45). Anxiously attached individuals are more prone to the persistent yearning and difficulty accepting the finality of loss that characterize PGD.
• Circumstances of death: Sudden, unexpected death; death perceived as preventable; and violent death all elevate PGD risk. COVID-19 deaths often combined suddenness (rapid deterioration), perceived preventability ("if only they had been vaccinated" or "if only hospitals hadn't been overwhelmed"), and traumatic circumstances (isolation, ventilator imagery).
• Pre-loss mental health: Pre-existing depression, anxiety disorders, and prior trauma exposure increase vulnerability. A history of prior losses, particularly unresolved losses, is a potent risk factor for cumulative grief.
• Social support: Low perceived social support is consistently associated with worse grief outcomes (r = −0.25 to −0.35 with grief severity). The pandemic's disruption of social support networks was thus a population-level risk factor amplifier.
• Concurrent stressors: Financial strain, caregiving burden, and exposure to multiple deaths — all common during the pandemic — compound grief risk through resource depletion.

Protective Factors

• Secure attachment style is the strongest psychological protective factor.
• Active coping strategies and cognitive flexibility predict better adjustment.
• Access to and engagement with cultural and religious mourning rituals is consistently associated with adaptive grief trajectories, making the pandemic disruption of these rituals particularly harmful.
• Meaning-making: The ability to make sense of the loss — to integrate it into a coherent life narrative — is a robust predictor of positive outcome. Sense-making is more difficult when death is perceived as random, unjust, or absurd, conditions that characterized many pandemic losses.

Pandemic-Specific Prognostic Considerations

Emerging data suggest that certain pandemic-specific factors predict worse grief trajectories: inability to say goodbye (odds ratio for PGD approximately 1.5–2.5 across studies), restricted funeral attendance, perceived inadequacy of medical care, and exposure to conspiracy theories or denial narratives about COVID-19 deaths. Conversely, some pandemic-bereaved individuals who were able to leverage technology for virtual connection, who had strong pre-existing social networks, and who found meaning through activism or memorialization appear to have shown resilient trajectories.

Several populations merit specific clinical attention in the context of pandemic grief.

Children and Adolescents

An estimated 10.5 million children worldwide lost a parent or caregiver to COVID-19 by mid-2022 (Hillis et al., The Lancet, 2022 update). Children's grief is frequently disenfranchised — adults may underestimate their understanding or capacity for grief. Developmentally, children below age 7 lack a full understanding of the irreversibility and universality of death, which shapes their grief expression (e.g., repeated questioning about when the person will return). Adolescents may express grief through behavioral dysregulation, risk-taking, or social withdrawal rather than overt sadness. PGD in children and adolescents has been associated with academic decline, increased risk for depression and anxiety disorders in adulthood, and insecure attachment patterns that may perpetuate intergenerational grief vulnerability. The DSM-5-TR specifies a 6-month rather than 12-month duration criterion for PGD in children and adolescents, reflecting recognition of the impact of developmental timing.

Older Adults

Older adults experienced disproportionate COVID-19 mortality and were simultaneously the population most isolated by public health restrictions. Many lost spouses, siblings, and lifelong friends — relationships whose irreplaceability intensifies grief. Age-related cognitive decline can complicate grief processing by impairing the cognitive flexibility needed for meaning-making and adaptive re-appraisal. However, older adults also demonstrate a well-documented "positivity effect" in emotional processing and often have greater experience with loss, which can be either a resource (accumulated coping skills) or a risk factor (cumulative grief burden). Pre-existing social isolation — present in approximately 25% of community-dwelling older adults pre-pandemic — was exacerbated by lockdowns and is a strong predictor of PGD in this population.

Healthcare Workers

The grief burden on healthcare workers during COVID-19 was extraordinary. A systematic review by Selman et al. (2022) found that healthcare workers reported significant grief symptoms related to patient deaths in 60–70% of surveyed samples, with approximately 20–30% meeting criteria for clinically significant grief or burnout complicated by grief. The concept of moral injury — distress from participation in events that transgress one's moral framework — is increasingly recognized as intertwined with healthcare worker grief. Workers who felt they had "failed" patients by being unable to prevent death or provide adequate comfort experienced grief compounded by guilt and shame, a pattern that predicts worse outcomes and is poorly addressed by standard grief interventions designed for personal bereavement.

Accurate identification of PGD requires validated measurement instruments, particularly in contexts where grief may be masked by comorbid conditions or disenfranchisement.

Key Instruments

• Inventory of Complicated Grief (ICG; Prigerson et al., 1995): The most widely used screening tool, consisting of 19 items rated on a 5-point Likert scale. A cutoff score of ≥30 has demonstrated good sensitivity (0.93) and specificity (0.88) for identifying PGD. The ICG was developed prior to the formal PGD diagnosis and thus does not map perfectly onto DSM-5-TR or ICD-11 criteria, but remains the most extensively validated instrument.
• Prolonged Grief-13 (PG-13; Prigerson et al., 2009): Specifically developed to assess the proposed diagnostic criteria for PGD. It includes duration and functional impairment criteria alongside symptom items, making it more diagnostically specific than the ICG.
• Brief Grief Questionnaire (BGQ): A 5-item screening tool suitable for primary care settings. Sensitivity is approximately 0.83 and specificity approximately 0.76, making it useful for initial screening but insufficient for diagnostic determination.
• Traumatic Grief Inventory Self-Report (TGI-SR; Boelen et al., 2019): An 18-item measure mapping onto both ICD-11 and DSM-5-TR criteria, developed to accommodate the newly formalized diagnosis. This instrument is increasingly used in research and has shown strong psychometric properties (Cronbach's alpha = 0.91–0.95).

Pandemic-Specific Assessment Considerations

Clinicians should assess for pandemic-specific risk factors that standard instruments may not capture: circumstances of the death (isolation, inability to visit), disruption of mourning rituals, concurrent non-death losses, exposure to multiple deaths, and the broader context of collective trauma. Instruments assessing disenfranchised grief are less well-developed; the Grief Experience Questionnaire (GEQ) includes items relevant to stigmatized loss but was not designed for pandemic contexts. Clinical interview remains essential for capturing the full picture of pandemic-era grief.

Despite significant advances, substantial gaps remain in the grief research literature, many of which the pandemic has highlighted or exacerbated.

Limitations of the Current Evidence Base

• Duration criterion debates: The 6-month (ICD-11) vs. 12-month (DSM-5-TR) discrepancy remains unresolved. Naturalistic studies suggest that early identification and intervention are beneficial, which favors the ICD-11 threshold, but the risk of pathologizing normal grief argues for conservative criteria. Longitudinal studies tracking grief trajectories in pandemic-bereaved cohorts are ongoing and will inform future revisions.
• Cultural validity: Most PGD research has been conducted in Western, educated, industrialized, rich, and democratic (WEIRD) populations. The cross-cultural validity of PGD diagnostic criteria is insufficiently established. Grief expression varies enormously: some cultures expect prolonged public mourning, others emphasize stoic acceptance. Applying Western diagnostic criteria without cultural adaptation risks both over-pathologizing normative cultural expressions and under-identifying genuine pathology in cultures where grief is expressed somatically or behaviorally rather than through the emotional symptoms emphasized in current criteria.
• Treatment outcome data are still predominantly from pre-pandemic studies. The CGT/PGDT and CBT trials were conducted with participants who were not, by and large, grieving in the context of a global pandemic. Whether treatment response rates generalize to pandemic-bereaved individuals — who may face ongoing collective trauma, multiple concurrent losses, and disenfranchisement — is an empirical question currently being investigated.
• Pharmacotherapy research is thin. The field lacks large, well-powered RCTs of pharmacological interventions for PGD. Given the substantial comorbidity with MDD and PTSD, many patients receive medications empirically, but the evidence base for these prescribing practices in PGD specifically is weak.

Emerging Research Directions

• Neurobiological biomarkers: Neuroimaging and neuroendocrine studies are attempting to identify biomarkers that distinguish PGD from normal grief and comorbid conditions. Preliminary data on altered resting-state functional connectivity patterns (particularly dmPFC–amygdala coupling) show promise but require replication.
• Computational phenotyping: Machine learning approaches applied to electronic health records and natural language processing of social media data are being explored for early identification of individuals at risk for PGD, potentially enabling preventive intervention.
• Preventive interventions: The question of whether early intervention in the acute bereavement period can prevent PGD development is being actively studied. Preliminary evidence suggests that brief, targeted interventions in the first 3–6 months post-loss may reduce PGD incidence, but the risk of medicalizing normal grief creates ethical tension.
• Collective trauma recovery: Research on how communities — not just individuals — recover from collective bereavement is in its early stages. Studies of post-pandemic memorialization, public mourning practices, and community-based grief support programs are underway but are largely descriptive rather than interventional.
• Long COVID and grief: An emerging area examines the intersection of long COVID symptoms (fatigue, cognitive impairment, mood dysregulation) with grief processing. Some investigators hypothesize that neuroinflammation associated with long COVID may biologically impair the neural plasticity required for adaptive grief processing, though this remains speculative.